A 48-year-old woman from Mumbai with familial hypercholesterolaemia (heterozygous) presents for lipid management. Her baseline lipid panel shows: total cholesterol 380 mg/dL, LDL 280 mg/dL, HDL 35 mg/dL, triglycerides 200 mg/dL. She has been on atorvastatin 80 mg daily for 2 years with inadequate LDL lowering. Her LDL receptor gene sequencing reveals a loss-of-function mutation. A PCSK9 inhibitor (evolocumab) is now added to her regimen. Which of the following best explains how PCSK9 inhibition achieves additional LDL lowering in this patient?

Explanation

## PCSK9 Inhibitors and LDL Receptor Recycling ### Clinical Context This patient has heterozygous familial hypercholesterolaemia (FH) due to an LDL receptor loss-of-function mutation. She has only ~50% of normal LDL receptor function. Despite high-dose statin therapy (which upregulates the remaining functional receptors), her LDL remains elevated. PCSK9 inhibitors offer a complementary mechanism that works synergistically with statins. ### Normal LDL Receptor Lifecycle ```mermaid flowchart TD A[LDL particle binds to LDL-R on hepatocyte surface]:::outcome --> B[Clathrin-mediated endocytosis]:::action B --> C[Endosomal internalisation]:::action C --> D[Acidic pH releases LDL from receptor]:::action D --> E[LDL → lysosomal degradation]:::action D --> F[LDL-R recycled to cell surface]:::action F --> G[Receptor available for new LDL binding]:::outcome H[PCSK9 binds to LDL-R in endosome]:::outcome --> I[Targets receptor for lysosomal degradation]:::urgent I --> J[Reduced LDL-R on cell surface]:::urgent ``` ### PCSK9 Function and Inhibition **Key Point:** PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) is a serine protease that binds to LDL receptors in the acidic endosomal compartment and targets them for lysosomal degradation instead of recycling to the cell surface. #### Normal PCSK9 Pathway 1. LDL-R internalises LDL via endocytosis 2. In the acidic endosome, PCSK9 binds to the LDL-R ectodomain 3. PCSK9 prevents the receptor from dissociating and recycling 4. The PCSK9–LDL-R complex is targeted to lysosomes for degradation 5. **Result:** Fewer LDL receptors on the hepatocyte surface → reduced LDL clearance #### PCSK9 Inhibition (Monoclonal Antibodies: Evolocumab, Alirocumab) 1. Antibodies bind to circulating PCSK9 and prevent it from reaching endosomal LDL-Rs 2. LDL-Rs are freed to recycle normally to the cell surface 3. **Result:** Increased LDL-R density on hepatocytes → enhanced LDL uptake and clearance **High-Yield:** PCSK9 inhibitors do NOT work by: - Inhibiting HMG-CoA reductase (that's statins) - Activating SREBP-2 (statins do this indirectly) - Blocking apoB-100 binding (that's not physiological) They work by **preserving LDL receptor recycling**, which is especially valuable in FH where receptor number is already limited. ### Why PCSK9 Inhibitors Are Synergistic with Statins | Agent | Mechanism | Effect on LDL-R | Effect on Cholesterol Synthesis | |-------|-----------|-----------------|--------------------------------| | **Statin** | Blocks HMG-CoA reductase | ↑ Upregulates LDL-R expression (via SREBP-2) | ↓ Reduces de novo synthesis | | **PCSK9 inhibitor** | Prevents LDL-R degradation | ↑ Increases LDL-R recycling & surface density | No direct effect | | **Combined** | Both mechanisms active | ↑↑ More receptors + longer half-life | ↓ Reduced synthesis + ↑↑ enhanced clearance | **Clinical Pearl:** In this patient with a defective LDL receptor gene, statins alone cannot fully compensate because the mutation limits how many functional receptors can be made. PCSK9 inhibitors maximise the use of the remaining functional receptors by preventing their premature degradation. ### LDL Lowering Efficacy - **Statin monotherapy:** ~50% LDL reduction - **Statin + PCSK9 inhibitor:** Additional 40–60% reduction from baseline (cumulative ~70–80% reduction) - **In heterozygous FH:** Can achieve near-normal LDL levels with combination therapy **Mnemonic:** **PCSK9 = Protease that Culls Surface Kinase-9** (it culls/removes LDL receptors from the surface by targeting them for degradation).